The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Allogene Therapeutics, Inc. (NASDAQ:ALLO) secured a spot on our list of the best penny stocks set to explode.

As of April 8, 2026, analyst sentiment toward Allogene Therapeutics, Inc. (NASDAQ:ALLO) remains bullish, with 85% of analysts issuing “Buy” ratings on the stock. The consensus price target of $7.50 implies an upside of 186.26%.

On March 13, 2026, Piper Sandler increased its price target from $7 to $8 and kept an “Overweight” rating on Allogene Therapeutics, Inc. (NASDAQ:ALLO). The firm stated that investor attention was shifting to the April interim analysis from the ALPHA3 study in first-line consolidation LBCL, while noting a favorable setup for cema-cel to achieve a 25%–30% MRD clearance advantage over observation.

This development followed Allogene Therapeutics, Inc. (NASDAQ:ALLO)’s March 12, 2026, Q4 and full-year 2025 results, in which management referred to ALPHA3 as a significant turning point, while also noting that the study may determine whether allogeneic CAR-T can be administered at a biologic-like scale and grow beyond academic centers.

Allogene Therapeutics, Inc. (NASDAQ:ALLO) has $258.3 million in cash, cash equivalents, and investments at the end of 2025, extending the company’s runway into Q1 2028, while guiding to $150 million in operating cash expenses in 2026. Net loss for the fourth quarter was $38.8 million ($0.17 per share) versus a full-year net loss of $190.9 million, or $0.87 per share.

Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a clinical-stage biotechnology company dedicated to the development of off-the-shelf allogeneic CAR-T cell therapies for cancer and autoimmune diseases. The company’s goal is to provide a scalable, readily available cell therapy derived from healthy donors.

While we acknowledge the potential of ALLO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.